TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27091542

Group type: EXPERIMENTAL
Intervention: Fixed-pressure CPAP (FP-CPAP)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Auto-adjusting CPAP (AutoCPAP)
Number of subjects: 322
Study: 24471505

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action (Gaviscon DA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 22293631

Group type: EXPERIMENTAL
Intervention: Genistein 300 mg/d
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Genistein 600 mg/d
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Genistein (combined arms)
Number of subjects: 59
Study: 20534746

Group type: EXPERIMENTAL
Intervention: Supplemental choline
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 17235043

Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg (loading dose of 840 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pertuzumab 1,050 mg
Number of subjects: 68
Study: 16240973

Group type: EXPERIMENTAL
Intervention: Usual care plus an offer of physician-led prayer
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 137
Study: 11895166

Group type: EXPERIMENTAL
Intervention: Black tea (one cup)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hot water (one cup)
Number of subjects: 20
Study: 10434168

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tropisetron 5 mg
Number of subjects: 88
Study: 7540758

Group type: EXPERIMENTAL
Intervention: Fetal artery thrombosis lesions
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intrauterine death cases (positive controls)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal control cases
Number of subjects: 35
Study: 2115045

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bromfenac
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 41
Study: 401699

Group type: EXPERIMENTAL
Intervention: Fenoprofen (2,400 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspirin (3,900 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gold induction therapy
Number of subjects: 40
Study: 30924190

Group type: EXPERIMENTAL
Intervention: Wellness Coaching Program
Number of subjects: 132

Group type: COMPARATOR
Intervention: Health Education Group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 132
Study: 28709630

Group type: EXPERIMENTAL
Intervention: Brazilian New Moves Program (multicomponent intervention aimed at preventing weight-related problems)
Number of subjects: 0
Study: 24786933

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccination (TIV)
Number of subjects: 0
Study: 23910402

Group type: EXPERIMENTAL
Intervention: Fresh scent (N = 79)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard environment (N = 86)
Number of subjects: 165
Study: 20649451

Group type: EXPERIMENTAL
Intervention: Immersive technology with emotionally related narrative
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Immersive technology without emotionally related narrative
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Non-immersive technology with emotionally related narrative
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-immersive technology without emotionally related narrative
Number of subjects: 84
Study: 19966607

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted sigmoidectomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Laparoscopic-facilitated sigmoidectomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 45
Study: 17827352

Group type: EXPERIMENTAL
Intervention: Intermittent preventive anti-malarial treatment (artesunate and sulfadoxine-pyrimethamine)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1063
Study: 15471830

Group type: EXPERIMENTAL
Intervention: Radionuclide therapy with 131I-MIBG (3.7-7.4 GBq, n = 5) or 111In-pentetreotide (7 GBq, n = 15) administered 3 times monthly
Number of subjects: 32
Study: 11532549

Group type: EXPERIMENTAL
Intervention: Motionless standing for 15 min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) at 80 degrees for 30 min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (normal children)
Number of subjects: 23
Study: 9760640

Group type: EXPERIMENTAL
Intervention: Feigned malingerers with warning
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Feigned malingerers without warning
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 8157852

Group type: EXPERIMENTAL
Intervention: 100% LCT
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50% LCT/50% MCT
Number of subjects: 20
Study: 3149935

Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Verapamil (V)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nitroglycerin (N) + Heparin (H)
Number of subjects: 85
Study: 29024080

Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty with rapid ventricular pacing (RP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balloon aortic valvuloplasty without rapid ventricular pacing (noRP)
Number of subjects: 100
Study: 27348075

Group type: EXPERIMENTAL
Intervention: Nomogram risk score derived from training cohort
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Age > 50 years
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Past excessive alcohol intake
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Low platelet count (<100 Giga/mm(3))
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Low platelet count ([100; 150] Giga/mm(3))
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Gamma‐glutamyl transpeptidase above the upper limit of normal
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Absence of a sustained virological response during follow‐up
Number of subjects: 1323
Study: 24184249

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 309
Study: 23653901

Group type: EXPERIMENTAL
Intervention: iBond Gluma inside (1‐SE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gluma Comfort Bond (2‐ER)
Number of subjects: 90
Study: 19364728

Group type: EXPERIMENTAL
Intervention: Raynaud's condition score (RCS) improvement group
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Raynaud's condition score (RCS)
Number of subjects: 162
Study: 18327721

Group type: EXPERIMENTAL
Intervention: Flu vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other interval estimators
Number of subjects: 0
Study: 15818640

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus manual therapy
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus pulsed shortwave diathermy
Number of subjects: 350

Group type: COMPARATOR
Intervention: Advice and exercise alone
Number of subjects: 350
Study: 12433711

Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids (SFAs)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Myristic acid (C14:0)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Palmitic acid (C16:0)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Total polyunsaturated fatty acids (PUFAs) (n-6 and n-3)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Individual n-3 fatty acids of marine origin (eicosapentaenoic acid (C20:5 n-3) and docosahexaenoic acid (C22:6 n-3))
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 197
Study: 10487668

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) plus HRT
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo plus HRT
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Alendronate plus HRT
Number of subjects: 428
Study: 9019933

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 0
Study: 1886590

Group type: COMPARATOR
Intervention: i.v. 5‐FU alone (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: i.v. 5‐FU with AT‐II (Group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: i.a. 5‐FU alone (Group C)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: i.a. 5‐FU with i.v. AT‐II (Group D)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: i.a. 5‐FU with AT‐II (Group E)
Number of subjects: 25
Study: 6620717

Group type: EXPERIMENTAL
Intervention: Topical phenylephrine (20 microliters of phenylephrine HCL 10%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31467049

Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XBJ), every 12 hours for 5 days
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XBJ)
Number of subjects: 1800
Study: 29908220

Group type: EXPERIMENTAL
Intervention: Automated quantitative mpMRI-based method for habitat risk scoring (HRS)
Number of subjects: 12
Study: 27036408

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) intervention, delivered online, single module, details on dosage and duration not specified.
Number of subjects: 600
Study: 24699050

Group type: EXPERIMENTAL
Intervention: Aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Warfarin therapy (international normalized ratio 2‐3)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (A+C)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 349
Study: 22251528

Group type: EXPERIMENTAL
Intervention: 3-week method of S-1 administration
Number of subjects: 146

Group type: COMPARATOR
Intervention: 4-week method of S-1 administration
Number of subjects: 146
Study: 19818846

Group type: EXPERIMENTAL
Intervention: Eccentric exercise immediately prior to vaccination
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Eccentric exercise 6 hours prior to vaccination
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Eccentric exercise 48 hours prior to vaccination
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 156
Study: 17116123

Group type: EXPERIMENTAL
Intervention: Oral rabeprazole 20 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg
Number of subjects: 38
Study: 16491579

Group type: EXPERIMENTAL
Intervention: High fiber meal at 2500 m
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low fiber meal at 2500 m
Number of subjects: 16
Study: 14605051

Group type: EXPERIMENTAL
Intervention: Antibiotics administered within 4 hours (group 1)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Antibiotics administered between 4 to 8 hours (group 2)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Antibiotics administered after 8 hours (group 3)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 409
Study: 10761530

Group type: EXPERIMENTAL
Intervention: Glycosylated G-CSF (lenograstim, 2 micrograms/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mutated G-CSF (nartograstim, 1 microgram/kg)
Number of subjects: 10
Study: 8881327

Group type: EXPERIMENTAL
Intervention: Manipulations based on categorization of concepts in reasoning problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conceptual knowledge influence
Number of subjects: 0
Study: 1579299

Group type: EXPERIMENTAL
Intervention: 5 g of 2% clindamycin vaginal cream daily for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: 500 mg metronidazole oral tablets twice a day for 7 days
Number of subjects: 48
Study: 6436861

Group type: EXPERIMENTAL
Intervention: Vincamine (4 X 20 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bromvincamine (4 X 20 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30682104

Group type: EXPERIMENTAL
Intervention: NEWS score
Number of subjects: 8204

Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 8204

Group type: EXPERIMENTAL
Intervention: SIRS score
Number of subjects: 8204
Study: 30480830

Group type: EXPERIMENTAL
Intervention: Fashion warning labels
Number of subjects: 118

Group type: COMPARATOR
Intervention: No warning labels
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Repeated exposure to warning labels
Number of subjects: 118
Study: 27367303

Group type: EXPERIMENTAL
Intervention: Structured skin self-examination (SSE) skills training intervention
Number of subjects: 494

Group type: COMPARATOR
Intervention: Customary care (control group)
Number of subjects: 494
Study: 25250626

Group type: EXPERIMENTAL
Intervention: Highest quartile of baseline dietary glycemic index (GI)
Number of subjects: 3583

Group type: EXPERIMENTAL
Intervention: Yearly updated dietary glycemic index (GI)
Number of subjects: 3583

Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL)
Number of subjects: 3583
Study: 23059577

Group type: EXPERIMENTAL
Intervention: Two-step self-etch adhesive (Clearfil Protect Bond) used in group 6
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional cavity conditioner (GC cavity conditioner) used in group 7
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse adhesive (Optibond FL) used in group 1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive (One Step Plus) used in group 2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Composite resin (APX) used in groups 1, 2, and 3
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer (Fuji II LC) used in groups 4, 5, 6, and 7
Number of subjects: 49
Study: 19888978

Group type: EXPERIMENTAL
Intervention: High EZH2 expression (>1.0%)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low p27(kip1) expression (<90%)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Significant disease presence
Number of subjects: 86
Study: 17490965

Group type: EXPERIMENTAL
Intervention: Intravenous trace element (TE) supplementation (copper, selenium, zinc) for 14-21 days
Number of subjects: 21
Study: 16202731

Group type: COMPARATOR
Intervention: HMR 3339 50 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: HMR 3339 2.5 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 118
Study: 11782615

Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b and ribavirin (5 MU/d for 4 weeks, 5 MU three times weekly for 8 weeks, then 3 MU three times weekly for 36 weeks)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard-dose interferon alfa-2b and ribavirin (for 48 weeks)
Number of subjects: 107
Study: 10524468

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine and bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study: 7742124

Group type: EXPERIMENTAL
Intervention: Digital luminescence radiography (DLR)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: High spatial frequency enhancement in DLR
Number of subjects: 326
Study: 1952438

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg given rectally every 4 h for three doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30
Study: 7037791

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (constant, variable dose infusion)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no nitroprusside)
Number of subjects: 18
Study: 30871907

Group type: EXPERIMENTAL
Intervention: Bone fixation technique using an interference screw for gracilis tendon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft-tissue fixation technique looping the gracilis tendon around the adductor magnus tendon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between techniques)
Number of subjects: 60
Study: 27930762

Group type: EXPERIMENTAL
Intervention: Standard-fractionation RT (70 Gy/35 over 7 weeks) plus cisplatin at 100 mg/m2 intravenous for 3 doses (arm A)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation RT (70 Gy/35 over 6 weeks) plus panitumumab at 9 mg/kg intravenous for 3 doses (arm B)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Standard-fractionation RT plus cisplatin (arm A)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation RT plus panitumumab (arm B)
Number of subjects: 320
Study: 26446978

Group type: EXPERIMENTAL
Intervention: RSA-BF training (5 weekly 45 min sessions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (daily stress diary once a week)
Number of subjects: 31
Study: 25123549

Group type: EXPERIMENTAL
Intervention: 75 mg ASA daily
Number of subjects: 186
Study: 21740452

Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus vitamins C and E (lansoprazole 30 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg BID for 14 days, plus vitamin C 500 mg BID and vitamin E 200 IU BID for 30 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard triple therapy (lansoprazole 30 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg BID for 14 days)
Number of subjects: 200
Study: 19710219

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrical stimulation (ES)
Number of subjects: 40
Study: 17259945

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day for 4 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15836567

Group type: EXPERIMENTAL
Intervention: BoNT‐A
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 11994827

Group type: EXPERIMENTAL
Intervention: Transdermal Therapeutic System (TTS) fentanyl with intramuscular Demerol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo system with intramuscular Demerol
Number of subjects: 32
Study: 9665006

Group type: EXPERIMENTAL
Intervention: CsA + Aza
Number of subjects: 83

Group type: COMPARATOR
Intervention: CsA + Pred
Number of subjects: 83
Study: 7516014

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg, single morning dose for 6 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 51
Study: 2465647

Group type: EXPERIMENTAL
Intervention: Irradiation + Surgery (Group 1 - 97 cases)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Surgery alone (Group 2 - 111 cases)
Number of subjects: 208
Study: 4911757

Group type: EXPERIMENTAL
Intervention: Quinidine bisulphate 1.5 g per day in two 12-hourly doses
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31969264

Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 243

Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 243

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: tDCS vs. escitalopram
Number of subjects: 243
Study: 31184266

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music through binaural headphones during pre-, intra-, and postprocedural periods)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 0
Study: 28542581

Group type: EXPERIMENTAL
Intervention: Bimanual condition with a ratio of 4:3 (4 taps against 3 sawing cycles per measure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimanual condition with a ratio of 3:4 (3 taps against 4 sawing cycles per measure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single handed tapping and sawing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free tapping
Number of subjects: 0
Study: 25919976

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Group A (IBD patients on no immunosuppressive therapy)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Group B (IBD patients on tumor necrosis factor agents or immunomodulators)
Number of subjects: 178
Study: 23918750

Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion (3 incremental doses: 0.27, 0.9, and 2.7 ng/kg per minute)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Angiotensin-(1-7) infusion with low sodium intake and/or angiotensin II co-infusion (0.3 ng/kg per minute)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion
Number of subjects: 57
Study: 22164500

Group type: EXPERIMENTAL
Intervention: Jian-gan-le
Number of subjects: 80

Group type: COMPARATOR
Intervention: Compound purple granules (Control)
Number of subjects: 80
Study: 19329178

Group type: EXPERIMENTAL
Intervention: Relaxin 30 microg/kg per day
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Relaxin (all doses)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 17082899

Group type: EXPERIMENTAL
Intervention: Subunit virus vaccine adjuvanted with MF59
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split virus vaccine
Number of subjects: 0
Study: 15023372

Group type: EXPERIMENTAL
Intervention: Varied post-natal lying positions (back, prone, and side) using a specially designed moldable mattress
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard lying position (stomach) with standard orthopaedic bolster support under hips
Number of subjects: 60